Published January 30, 2025 | Version v1
Publication Open

A Comprehensive Diagnostic and Treatment Framework for Pancreatic Cancer Patients with Comorbidities

  • 1. MD, PhD, Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
  • 2. MD, MS, Weill Cornell Medical College of Cornell University
  • 3. MD, MS, Nexus Alliance Biopharma
  • 4. Ms, Islamic Azad University
  • 5. PharmD, Nexus Alliance Biopharma
  • 6. Student at the University of Florida
  • 7. Student at York University, Toronto, ON
  • 8. Student at Valencia College

Description

Abstract
Pancreatic cancer remains a challenging malignancy with a high mortality rate. Comorbidities such as chronic pancreatitis, diabetes mellitus, obesity, and metabolic syndrome exacerbate diagnostic and treatment challenges, significantly influencing outcomes. [1] This study evaluates the impact of comprehensive comorbidity management including glycemic control, weight management, and anti-inflammatory therapies, on overall survival (OS) and overall response rate (ORR). [2] Analysis of 2,600 biomarker datasets and 124 patient records from a retrospective cohort revealed that effective comorbidity management was associated with improved OS (hazard ratio: 0.75 [95% CI, 0.65–0.85]; p < 0.01) and ORR (response rate: 45% vs. 30%, p = 0.02) compared to patients with unmanaged conditions. A comparative analysis with population-based registry data further highlights the need to tailor diagnostic and therapeutic strategies for high-risk cohorts, emphasizing the importance of addressing comorbidities in pancreatic cancer management. [3].

Files

JMRCR-07-0064.pdf

Files (485.2 kB)

Name Size Download all
md5:e8df695a56415da86eb603d47f06ae22
485.2 kB Preview Download